Chai Discovery closed a $130 million Series B led by Oak HC/FT and General Catalyst, bringing the AI-native drug developer’s valuation to roughly $1.3 billion. The company said it will deploy the capital to expand its computational design suite, including Chai 2, which the team used to create antibody candidates described in a recent preprint. Chai also added former industry executives to its board and emphasized downstream partnerships with pharma. "AI-native" refers to biotechs that build drug-discovery platforms around machine learning models rather than traditional wet-lab processes.